Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Jan 28, 2009


DxS announced this week the appointment of Jeff Devlin as chief operating officer. Prior to DxS, Devlin was executive VP and executive committee member of Shire Pharmaceuticals, and a partner in Ernst and Young's life science division.

The company noted that Devlin's appointment is one of a number of new promotions and hires planned for 2009. DxS has doubled its workforce size in the last year after opening a new manufacturing space in Manchester, UK, and signing a global distribution deal with Roche Molecular Diagnostics for its TheraScreen diagnostic kits.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.